Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection von Shah, Ashish H., Mahavadi, Anil, Di, Long, Sanjurjo, Alexander, Eichberg, Daniel G., Borowy, Veronica, Figueroa, Javier, Luther, Evan, de la Fuente, Macarena Ines, Semonche, Alexa, Ivan, Michael E., Komotar, Ricardo J.

Volltext

Therapies for IDH-Mutant Gliomas von Alshiekh Nasany, Ruham, de la Fuente, Macarena Ines

Volltext

Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results von Sherman, Eric Jeffrey, De La Fuente, Macarena Ines, Yaeger, Rona, Tsai, Frank Yung-Chin, Janku, Filip, Butowski, Nicholas A., Allen, Carl E., Ammakkanavar, Natraj Reddy, Taylor, Jennie Webster, Samara, Emil, Mould, Diane R., Michelson, Glenn, Kline, Irina, Paz, Michael, Tussay-Lindenberg, Alexia, Wong, Kongming, Shepherd, Stacie Peacock, Jiang, Ping, Rodon Ahnert, Jordi

Volltext

Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study von De La Fuente, Macarena Ines, Rodon Ahnert, Jordi, Yaeger, Rona, Tsai, Frank Yung-Chin, Janku, Filip, Butowski, Nicholas A., Allen, Carl E., Ammakkanavar, Natraj Reddy, Taylor, Jennie Webster, Michelson, Glenn, Kline, Irina, Paz, Michael, Tussay-Lindenberg, Alexia, Wong, Kongming, Shepherd, Stacie Peacock, Jiang, Ping, Sherman, Eric Jeffrey

Volltext

NIMG-41. ENHANCING TUMOR VOLUME AT RECURRENCE AS A PREDICTOR OF GLIOBLASTOMA GROWTH von Diaz, Roberto Jose, Fuente, Macarena Ines De La

Volltext

Binocular radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma von De La Fuente, Macarena Ines, Alderuccio, Juan Pablo, Markoe, Arnold M., Davis, Janet L., Lossos, Izidore S.

Volltext

Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma von Reardon, David A., Brem, Steven, Desai, Arati Suvas, Bagley, Stephen Joseph, Kurz, Sylvia Christine, De La Fuente, Macarena Ines, Nagpal, Seema, Welch, Mary Roberta, Hormigo, Adilia, Forsyth, Peter A. J., Mandel, Jacob Joseph, Khagi, Simon, Aiken, Robert, Walbert, Tobias, Lieberman, Frank S., Portnow, Jana, Battiste, James, Gillespie, Elisabeth, Lowy, Israel, Skolnik, Jeffrey

Volltext

Molecular features of gliomas with high tumor mutational burden von Xiu, Joanne, Walsh, Kyle M, Pandey, Manjari, Lou, Emil, Fonkem, Ekokobe, Newton, Herbert B., Dunbar, Erin M., De La Fuente, Macarena Ines, Glantz, Michael J., Mittal, Sandeep, Ashley, David M., Korn, Wolfgang Michael, Sumrall, Ashley Love

Volltext

Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas von Brastianos, Priscilla Kaliopi, Twohy, Erin, Geyer, Susan Michelle, Gerstner, Elizabeth Robins, Kaufmann, Timothy J., Ruff, Michael, Bota, Daniela Annenelie, Reardon, David A., Cohen, Adam Louis, De La Fuente, Macarena Ines, Lesser, Glenn Jay, Campian, Jian Li, Agarwalla, Pankaj, Kumthekar, Priya, Cahill, Daniel P., Shih, Helen Alice, Brown, Paul D., Santagata, Sandro, Barker, Frederick G., Galanis, Evanthia

Volltext

INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate... von Mellinghoff, Ingo K., Van Den Bent, Martin J., Clarke, Jennifer Leigh, Maher, Elizabeth Anne, Peters, Katherine B., Touat, Mehdi, De Groot, John Frederick, De La Fuente, Macarena Ines, Arrillaga-Romany, Isabel, Wick, Wolfgang, Ellingson, Benjamin M., Schoenfeld, Steven, Tai, Feng, Le, Kha, Lu, Min, Steelman, Lori, Hassan, Islam, Pandya, Shuchi Sumant, Wen, Patrick Y., Cloughesy, Timothy Francis

Volltext

INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results von Reardon, David A., Brem, Steven, Desai, Arati Suvas, Bagley, Stephen Joseph, Kurz, Sylvia Christine, De La Fuente, Macarena Ines, Nagpal, Seema, Welch, Mary Roberta, Hormigo, Adilia, Carroll, Nicholas, Bartra, Sarah K, Campbell, Patricia, Bhatt, Kamalnayan, Lowy, Israel, Boyer, Jean, Kraynyak, Kimberly, Morrow, Matthew P, McMullan, Trevor, Weiner, David B., Skolnik, Jeffrey

Volltext

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine von De La Fuente, Macarena Ines, Colman, Howard, Rosenthal, Mark, Van Tine, Brian Andrew, Levaci, Danijela, Walbert, Tobias, Gan, Hui Kong, Vieito, Maria, Milhem, Mohammed M., Lipford, Kate, Forsyth, Sanjeev, Guichard, Sylvie Mireille, Mikhailov, Yelena, Sedkov, Alexander, Thomson, Blythe, Kelly, Patrick Francis, Monga, Varun

Volltext

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent von Jones, Robin Lewis, Macarulla, Teresa, Charlson, John A., Van Tine, Brian Andrew, Goyal, Lipika, Italiano, Antoine, Massard, Christophe, Rosenthal, Mark, De La Fuente, Macarena Ines, Roxburgh, Patricia, Kundranda, Madappa N., Blay, Jean-Yves, Yoo, Changhoon, Lipford, Kate, Forsyth, Sanjeev, Guichard, Sylvie Mireille, Mikhailov, Yelena, Thomson, Blythe, Kelly, Patrick Francis, Duffaud, Florence

Volltext

Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma populati... von Mellinghoff, Ingo K., Peters, Katherine B., Cloughesy, Timothy Francis, Burris III, Howard A., Maher, Elizabeth Anne, Janku, Filip, Cote, Gregory Michael, De La Fuente, Macarena Ines, Clarke, Jennifer Leigh, Le, Kha, Liu, Li, Yuen, Man, Arnofsky, Marissa, Hassan, Islam, Steelman, Lori, Pandya, Shuchi Sumant, Wen, Patrick Y.

Volltext

ACTR-43. PILOT STUDY OF OPTUNE (NOVOTTF-100A) FOR RECURRENT ATYPICAL AND ANAPLASTIC MENINGIOMA von Wu, Synphen, Gavrilovec, Igor, De La Fuente, Macarena Ines, Kreisl, Teri, Kaley, Thomas

Volltext

Outcomes in patients with marginal zone lymphomas undergoing transformation to high-grade lymphomas von Alderuccio, Juan Pablo, Desai, Amrita, Gallastegui Crestani, Nicolas, Ramdial, Jeremy, Kimble, Erik Lesley, De La Fuente, Macarena Ines, Chapman, Jennifer, Vega, Francisco, Zhao, Wei, Reis, Isildinha M., Lossos, Izidore S.

Volltext

LTBK-01. INO-5401 AND INO-9012 DELIVERED INTRAMUSCULARLY (IM) WITH ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB (REGN2810) IN NEWLY DIAGNOSED GLIOBLASTOMA von Reardon, David A, Brem, Steven, Desai, Arati Suvas, Bagley, Stephen Joseph, Kurz, Sylvia Christine, De La Fuente, Macarena Ines, Nagpal, Seema, Welch, Mary Roberta, Hormigo, Adilia, Forsyth, Peter, Mandell, Jacob, Khagi, Simon, Aiken, Robert, Walbert, Tobias, Lieberman, Frank, Portnow, Jana, Batiste, James, Carroll, Nicholas, Sylvester, Albert, Campbell, Patricia, Lowy, Israel, Dolgoter, Alex, Boyer, Jean, Kraynyak, Kimberly, Morrow, Matthew P, McMullan, Trevor, Weiner, David B, Skolnik, Jeffrey

Volltext

Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma von Mellinghoff, Ingo K., Penas-Prado, Marta, Peters, Katherine B., Cloughesy, Timothy Francis, Burris, Howard A., Maher, Elizabeth A., Janku, Filip, Cote, Gregory Michael, De La Fuente, Macarena Ines, Clarke, Jennifer, Steelman, Lori, Le, Kha, Zhang, Yanwei, Sonderfan, Alison, Hummel, Diana, Schoenfeld, Steven, Yen, Katharine, Pandya, Shuchi Sumant, Wen, Patrick Y.

Volltext

Insecticidal effect of hydroalcoholic extracts of Pleurotus ostreatus against Sitophilus zeamais von Palavecino-De-La-Fuente, Fernanda, Silva-Aguayo, Gonzalo, Figueroa-Cares, Ines, Gerding, Macarena, Concepcion Rodriguez-Maciel, Jose Maciel, Angel Lagunes-Tejeda, Castaneda-Ramirez, Gloria Sarahi, Sotelo-Leyva, Cesar, Curkovic, Tomislav, Aguilar-Marcelino, Liliana

Volltext